Wrap Text
ASPI announces that Renergen Limited’s Subsidiary has entered into a Take-or-Pay contract
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
ASPI ANNOUNCES THAT RENERGEN LIMITED'S SUBSIDIARY HAS ENTERED INTO A
TAKE-OR-PAY CONTRACT FOR THE SUPPLY OF LIQUIFIED NATURAL GAS TO BE PRODUCED AT
THE VIRGINIA GAS PROJECT IN SOUTH AFRICA
Tetra4, a subsidiary of Renergen and the developer of the Virginia Gas Project, has entered into an
additional take-or-pay contract to supply liquified natural gas (LNG) to a domestic food processor,
establishing a multi-year contracted cash flow supporting Phase 1 commercial operations, which
remain targeted for completion in the third quarter of 2026
The LNG sale and purchase agreement, which is a five-year take-or-pay contract, is priced at greater
than $16 /GJ (0.9478 MMBtu) of LNG, at current exchange rates
Following the execution of this contract, Renergen has now secured take-or-pay contracts to support
approximately 75% of the LNG volumes anticipated from Phase 1
The Company is in discussions with multiple other potential customers and expects to complete
contracting for Phase 1 volumes for both the liquid helium and LNG produced from Phase 1 during 3Q 2026
DALLAS, August 06, 2026 - ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or the "Company"),
an advanced materials company focused on developing technologies and processes for the production
of critical materials used in multiple industries, today announced that Tetra4 Proprietary Limited, a
subsidiary of Renergen Limited ("Renergen") and the developer of the Virginia Gas Project, has entered
into a new contract for the sale of liquified natural gas (LNG) to be produced at the Virginia Gas Project
in the Free State, South Africa.
"South Africa's domestic energy situation has proved challenging during recent years with multiple load
shedding events and energy blackouts", said Paul Mann, Executive Chairman and Chief Executive
Officer of ASP Isotopes. "The associated LNG produced from the Virginia Gas Project is welcomed by
local industrial businesses to support their energy needs. We look forward to completing the
construction of Phase 1 and, in addition to supplying domestic customers with LNG, starting to supply
international customers with liquid helium at a point in time when geopolitical issues have greatly
constricted the supply of this critical material."
The LNG sale and purchase agreement is a five-year, take-or-pay contract with a South African food
processor at a price per unit of greater than $16/ GJ (MMBtu) of LNG (at current exchange rates), on
an all-in plant-gate basis, and represents approximately 10% of the project's Phase 1 nameplate
capacity.
Phase 1 is expected to produce approximately 2,500 GJ/day of LNG and approximately 70 Mcf/day of
liquid helium, with commercial production expected to commence during the third quarter of 2026. As
set out in the Company's shareholder letter dated August 4, 2026 (here), and assuming $15–18 per GJ
(0.9478 MMBtu) for LNG and an average of $600/ Mcf for liquid helium, Renergen should be capable
of generating revenues of over $27 million on an annualized basis following the expected completion
of Phase 1. The Company expects to begin recognizing these revenues during 2H 2026.
The Company is in active discussions with additional potential customers regarding offtake of both LNG
and liquid helium from both Phase 1 and Phase 2. The Company expects to complete contracting for
Phase 1 during 3Q 2026 and commence contracting for a significant portion of the expected Phase 2
volumes during the second half of 2026.
About ASP Isotopes Inc.
ASP Isotopes is developing a differentiated isotope enrichment platform to strengthen global supply
chain access to critical materials used in nuclear medicine, next-generation semiconductors, and
nuclear energy. The Company's proprietary technologies, the Aerodynamic Separation Process ("ASP
technology") and Quantum Enrichment ("QE technology"), are designed to enable the production of
isotopes for a range of industrial and advanced technology applications. ASP Isotopes operates isotope
enrichment facilities in Pretoria, South Africa, focused on the enrichment of low atomic mass elements,
or light isotopes. For more information, please visit www.aspisotopes.com.
About Renergen
Renergen Limited, a subsidiary of ASP Isotopes Inc., is a company incorporated under the laws of the
Republic of South Africa whose principal asset is its 94.5% equity ownership in Tetra4 Proprietary
Limited. Tetra4 Proprietary Limited holds an onshore petroleum production right and engages in the
production and liquefaction of natural gas and the exploration and development of helium resources at
the Virginia Gas Plant located in Free State Province, South Africa.
Important Additional Information and Where to Find It
In connection with the proposed merger and related transactions (the "Proposed Transactions")
involving ENDRA Life Sciences Inc. ("ENDRA"), ASP Isotopes, Renergen, and Noble Africa, a
subsidiary of ASP Isotopes and future holding company for Renergen ("Noble Africa"), ENDRA intends
to file relevant materials with the U.S. Securities and Exchange Commission (the "SEC"), including a
registration statement on Form S-4 (the "Form S-4"), that will contain a proxy statement (the "Proxy
Statement") and prospectus. This communication is not a substitute for the Form S-4, the Proxy
Statement or for any other document that ENDRA may file with the SEC and/or send to its stockholders
in connection with the Proposed Transactions. INVESTORS AND STOCKHOLDERS OF ENDRA ARE
URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT
DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR
SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN
THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT
ENDRA, ASP ISOTOPES, RENERGEN, NOBLE AFRICA, THE PROPOSED TRANSACTIONS AND
RELATED MATTERS. Investors and stockholders will be able to obtain free copies of the Form S-4,
the Proxy Statement and other documents filed by ENDRA and ASP Isotopes with the SEC (when they
become available) through the website maintained by the SEC at www.sec.gov. ENDRA's Internet
website address is www.endrainc.com. ENDRA's Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q, Current Reports on Form 8-K, including exhibits, and amendments to those reports filed or
furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge through
the investor relations page of its Internet website as soon as reasonably practicable after it electronically
files such material with, or furnishes such material to, the SEC.
Participants in the Solicitation
ENDRA, ASP Isotopes, Renergen, Noble Africa, and their respective directors and managers and
certain of their executive officers and other members of management may be deemed to be participants
in the solicitation of proxies from ENDRA's stockholders in connection with the Proposed Transactions
under the rules of the SEC. Information about ENDRA's directors and executive officers, including a
description of their interests in ENDRA, is included in ENDRA's most recent Annual Report on Form
10-K for the year ended December 31, 2025. Information about ASP Isotopes' directors and executive
officers, including a description of their interests in ASP Isotopes, is included in ASP Isotopes' most
recent Annual Report on Form 10-K for the year ended December 31, 2025. Additional information
regarding the persons who may be deemed participants in the proxy solicitations, including the directors
and executive officers of Renergen, and a description of their direct and indirect interests, by security
holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant
materials to be filed with the SEC when they become available. These documents can be obtained free
of charge from the sources indicated above.
No Offer or Solicitation
This press release is not intended to and does not constitute a solicitation of a proxy, consent or
approval with respect to any securities or in respect of the Proposed Transactions or an offer to sell or
the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any
securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or
transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall
be made except by means of a prospectus meeting the requirements of Section 10 of the Securities
Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom.
Subject to certain exceptions to be approved by the relevant regulators or certain facts to be
ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do
so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means
or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of
interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.
Cautionary Statement Regarding Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are
neither historical facts nor assurances of future performance. Instead, they are based only on our
current beliefs, expectations, and assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and trends, the economy, and other future conditions.
Forward-looking statements can be identified by words such as "believes," "plans," "anticipates,"
"expects," "estimates," "projects," "will," "may," "might," and words of a similar nature. Examples of
forward-looking statements include, among others but are not limited to, statements we make regarding:
the anticipated production quantities and timing for the commencement of commercial supply of helium
and LNG upon completion of Phase 1 and 2 of the Renergen helium project; the impact of the conflict
in the Middle East and the closure of the Strait of Hormuz on the helium market; the anticipated progress
and timing for completion of Phase 1 and 2 of the Renergen helium project; the ability to fund completion
of the development of the Renergen helium project (including the ability to negotiate and enter into
binding definitive agreements with the U.S. International Development Finance Corporation and
Standard Bank of South Africa for senior debt funding for Phase 2 of the Renergen helium project);
anticipated production quantities and the completion of the Noble Africa reverse merger and private
placement and other transactions in the anticipated timeframe or at all; expectations regarding the
structure, timing and completion of the Noble Africa reverse merger, including investment amounts from
investors, timing of closing of the Noble Africa reverse merger, expected proceeds, expectations
regarding the use of proceeds, and impact on ownership structure; the Noble Africa reverse merger and
the expected effects, perceived benefits or opportunities of the Noble Africa reverse merger; the
combined company's listing on Nasdaq after the closing of the Noble Africa reverse merger; the
anticipated timing of the closing of the Noble Africa reverse merger; and statements we make regarding
expected operating results, such as future revenues and prospects from the potential commercialization
of helium and LNG, future performance under contracts, and our strategies for Renergen Helium Project
development or extraction of resources, engaging with potential customers, market position, and
financial results. Because forward-looking statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are difficult to predict, many of which are outside
our control. Our actual results, financial condition, and events may differ materially from those indicated
in the forward-looking statements based upon a number of factors. Forward-looking statements are not
a guarantee of future performance or developments. You are strongly cautioned that reliance on any
forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should
not rely on any of these forward-looking statements.
There are many important factors that could cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements, including, but not limited to: the
outcomes of various strategies and projects undertaken by the Company; the potential impact of laws
or government regulations or policies in South Africa, the United Kingdom or elsewhere; our future
capital requirements and sources and uses of cash; our ability to obtain funding for our operations and
future growth; our ability to negotiate and enter into binding definitive agreements with U.S. International
Development Finance Corporation and Standard Bank of South Africa for senior debt funding for Phase
2 of the Renergen helium project on terms that are favorable, or at all; our reliance on the efforts of third
parties; the financial terms of any current and future commercial arrangements; our ability to complete
certain transactions and realize anticipated benefits from acquisitions; contracts, dependence on our
Intellectual Property (IP) rights, certain IP rights of third parties; the competitive nature of our industry;
risks related to the consummation of the proposed reverse merger of Noble Africa with ENDRA Life
Sciences in the anticipated timeframe, if at all; the satisfaction of the scheme conditions; the failure to
obtain necessary regulatory approvals and third party consents; if consummated, the ability to realize
the anticipated benefits of the proposed reverse merger of Noble Africa with ENDRA; the ability to
successfully integrate the businesses; disruption from the proposed reverse merger of Noble Africa with
ENDRA making it more difficult to maintain business and operational relationships; the negative effects
of the consummation of the proposed reverse merger of Noble Africa with ENDRA on the market price
of Noble Africa's or ASPI's securities; the risk that the proposed financings are not completed in a timely
manner, if at all; risks related to ENDRA's continued listing on Nasdaq until closing of the proposed
reverse merger and the combined company's ability to remain listed following the closing of the reverse
merger; significant transaction costs and unknown liabilities, and litigation or regulatory actions related
to the proposed reverse merger of Noble Africa with ENDRA; and the factors disclosed in Part I, Item
1A. "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended December 31,
2025 and any subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange
Commission. Any forward-looking statement made by us in this press release is based only on
information currently available to us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement, whether as a result of new information,
future developments or otherwise.
In addition, this press release includes market and industry data and forecasts that we obtained from
internal research, publicly available information and industry publications and surveys. Industry
publications and surveys generally state that the information contained therein has been obtained from
sources believed to be reliable. Unless otherwise noted, statements as to our potential market position
relative to other companies are approximated and based on third-party data and internal analysis and
estimates as of the date of this press release. We have not independently verified this information, and
it could prove inaccurate. Industry and market data could be wrong because of the method by which
sources obtained their data and because information cannot always be verified with certainty due to the
limits on the availability and reliability of raw data, the voluntary nature of the data-gathering process
and other limitations and uncertainties. In addition, we do not know all of the assumptions regarding
general economic conditions or growth that were used in preparing the information and forecasts from
sources used by us. No information in this press release should be interpreted as an indication of future
success, revenues, results of operation, or stock price.
All forward-looking statements herein are qualified by reference to the cautionary statements set forth
herein and should not be relied upon.
Use of Projections
The financial outlook and projections, estimates and targets in this press release are forward-looking
statements that are based on assumptions that are inherently subject to significant uncertainty and
contingencies, many of which are beyond ASP Isotopes' control. Any such calculation, at this time,
would imply a degree of precision that could be confusing or misleading to investors. Neither ASP
Isotopes nor Renergen's independent auditors have audited, reviewed, compiled or performed any
procedures with respect to the financial projections for purposes of inclusion in this press release, and,
accordingly, they did not express an opinion or provide any other form of assurance with respect thereto
for the purposes of this press release. While all financial projections, estimates and targets are
necessarily speculative, ASP Isotopes believes that the preparation of prospective financial information
involves increasingly higher levels of uncertainty the further out the projection, estimate or target
extends from the date of preparation. The assumptions and estimates underlying the projected,
expected or target results for ASP Isotopes and its subsidiaries are inherently uncertain and are subject
to a wide variety of significant business, economic and competitive risks and uncertainties that could
cause actual results to differ materially from those contained in the financial projections, estimates and
targets. The inclusion of financial projections, estimates and targets in this press release should not be
regarded as an indication that ASP Isotopes, or its representatives, considered or consider the financial
projections, estimates or targets to be a reliable prediction of future events. Further, inclusion of the
prospective financial information in this press release should not be regarded as a representation by
any person that the results contained in the prospective financial information will be achieved.
Contact
IR@ASPIsotopes.com
The Company has a primary listing on the Nasdaq and a secondary listing on the Main Board of the
JSE.
6 August 2026
Sponsor
Valeo Capital Proprietary Limited
Date: 06-08-2026 02:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
